Cancer Causes & Control

, Volume 21, Issue 6, pp 811–820 | Cite as

A bupropion smoking cessation clinical trial for cancer patients

  • Robert A. SchnollEmail author
  • Elisa Martinez
  • Kristina L. Tatum
  • Dorothy M. Weber
  • Natalie Kuzla
  • Marcella Glass
  • John A. Ridge
  • Corey Langer
  • Curtis Miyamoto
  • E. Paul Wileyto
  • Frank Leone
Original paper



Many cancer patients continue to smoke post diagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation.


This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7-day point-prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.


There was no main effect of bupropion vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38–4.81, p = .64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02–0.80, p = .03). Bupropion increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, bupropion reduced withdrawal symptoms and improved quality of life vs. placebo.


For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with bupropion or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.


Cancer patients Smoking Bupropion Depression 



The authors would like to thank Ms. Jeanne Pomenti for assisting with the preparation of this manuscript. This study was funded by grant R01 CA95678 from the National Cancer Institute. Transdermal nicotine patches were provided free-of-charge by GlaxoSmithKline. All sites provided Institutional Review Board approval. All patients provided informed consent for this study.


  1. 1.
    Videtic GM, Stitt LW, Dar AR et al (2003) Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncl 21:1544–1549CrossRefGoogle Scholar
  2. 2.
    Schnoll RA, James C, Malstrom M et al (2003) Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med 25:214–222CrossRefPubMedGoogle Scholar
  3. 3.
    Walker MS, Vidrine DJ, Gritz ER et al (2006) Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev 15:2370–2377CrossRefPubMedGoogle Scholar
  4. 4.
    Zhou W, Heist RS, Liu G et al (2006) Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer 53:375–380CrossRefPubMedGoogle Scholar
  5. 5.
    Garces YI, Schroeder DR, Nirelli LM et al (2007) Second primary tumors following tobacco dependence treatments among head and neck cancer patients. Am J Clin Oncol 30:531–539CrossRefPubMedGoogle Scholar
  6. 6.
    Browman GP, Mohide EA, Willan A et al (2002) Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. Head Neck 24:1031–1037CrossRefPubMedGoogle Scholar
  7. 7.
    Carter CL, Key J, Marsh L et al (2001) Contemporary perspectives in tobacco cessation: what oncologists need to know. Oncologist 6:496–505CrossRefPubMedGoogle Scholar
  8. 8.
    Tsao As, Liu D, Lee JJ, Sptiz M, Hong WK (2006) Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428–2436CrossRefPubMedGoogle Scholar
  9. 9.
    Rades D, Setter C, Schild SE, Dunst J (2008) Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71:1134–1142PubMedGoogle Scholar
  10. 10.
    Vander Ark W, DiNardo LJ, Oliver DS (1997) Factors affecting smoking cessation in patients with head and neck cancer. Laryngoscope 107:888–892CrossRefPubMedGoogle Scholar
  11. 11.
    Duarte RL, Luiz RR, Paschoal ME (2008) The cigarette burden (measured by the number of pack years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients. Lung Cancer 61:244–254CrossRefPubMedGoogle Scholar
  12. 12.
    Baser S, Shannon VR, Eapen GA et al (2006) Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 130:1784–1790CrossRefPubMedGoogle Scholar
  13. 13.
    Gritz ER, Fingeret MC, Vidrine DJ et al (2006) Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 106:17–27CrossRefPubMedGoogle Scholar
  14. 14.
    Gritz ER, Vidrine DJ, Fingeret MC (2007) Smoking cessation a critical component of medical management in chronic disease populations. Am J Prev Med 33:S414–S422CrossRefPubMedGoogle Scholar
  15. 15.
    Gritz ER, Carr CR, Rapkin D et al (1993) Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 2:261–270PubMedGoogle Scholar
  16. 16.
    Schnoll RA, Zhang B, Rue M et al (2003) Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 21:355–365CrossRefPubMedGoogle Scholar
  17. 17.
    Schnoll RA, Rothman RL, Wielt DB et al (2005) A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Ann Behav Med 30:1–11CrossRefPubMedGoogle Scholar
  18. 18.
    Schnoll RA, Malstrom M, James C et al (2002) Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns 46:137–145CrossRefPubMedGoogle Scholar
  19. 19.
    Covey LS, Glassman AH, Stetner F (1990) Depression and depressive symptoms in smoking cessation. Compr Psychiatry 31:350–354CrossRefPubMedGoogle Scholar
  20. 20.
    Hayford KE, Patten CA, Rummans TA et al (1999) Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174:173–178CrossRefPubMedGoogle Scholar
  21. 21.
    Hughes JR (1992) Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60:689–697CrossRefPubMedGoogle Scholar
  22. 22.
    Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr 32:32–39CrossRefPubMedGoogle Scholar
  23. 23.
    van Wilgen CP, Dijkstra PU, Stewart RE et al (2006) Measuring somatic symptoms with the CES-D to assess depression in cancer patients after treatment: comparison among patients with oral/oropharyngeal, gynecological, colorectal, and breast cancer. Psychosomatics 47:465–470CrossRefPubMedGoogle Scholar
  24. 24.
    Lerman C, Roth D, Kaufmann V et al (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219–223CrossRefPubMedGoogle Scholar
  25. 25.
    Catley D, Harris KJ, Okuyemi KS et al (2005) The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. Nicotine Tob Res 7:859–870CrossRefPubMedGoogle Scholar
  26. 26.
    Hitsman B, Pingitore R, Spring B et al (1999) Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 67:547–554CrossRefPubMedGoogle Scholar
  27. 27.
    Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMedGoogle Scholar
  28. 28.
    Martinez E, Tatum KL, Weber DM, et al (2009) Issues related to implementing a smoking cessation clinical trial for cancer patients. Cancer Causes Control 20:97–104CrossRefPubMedGoogle Scholar
  29. 29.
    Radloff L (1977) The CES-D scale: a new self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRefGoogle Scholar
  30. 30.
    Heatherton TF, Kozlowski LT, Frecker RC et al (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119–1127CrossRefPubMedGoogle Scholar
  31. 31.
    de Graeff A, de Leeuw JR, Ros WJ et al (2000) Pretreatment factors predicting quality of life after treatment for head and neck cancer. Head Neck 22:398–407CrossRefPubMedGoogle Scholar
  32. 32.
    Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063–1070CrossRefPubMedGoogle Scholar
  33. 33.
    Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289–294PubMedGoogle Scholar
  34. 34.
    Heil SH, Higgins ST, Mongeon JA et al (2006) Characterizing nicotine withdrawal in pregnant cigarette smokers. Exp Clin Psychopharmacol 14:165–170CrossRefPubMedGoogle Scholar
  35. 35.
    Brown R, Burgess E, Sales S et al (1998) Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav 12:101–112CrossRefGoogle Scholar
  36. 36.
    Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233CrossRefPubMedGoogle Scholar
  37. 37.
    McCorkle R, Dowd M, Ercolano E, et al (2009) Effects of a nursing intervention on quality of life outcomes in post-surgical women with gynecological cancers. Psychooncology 18:62–70CrossRefPubMedGoogle Scholar
  38. 38.
    Gandek B, Ware JE, Aaronson NK et al (1998) Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51:1171–1178CrossRefPubMedGoogle Scholar
  39. 39.
    Fiore MC, Jaén CR, Baker TB, et al (2008) Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, May 2008Google Scholar
  40. 40.
    Glaxo_Wellcome (1999) Bupropion hydrochloride sustained-release tablets prescribing information. Research Triangle Park, North Carolina, USAGoogle Scholar
  41. 41.
    Holm KJ, Spencer CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007–1024CrossRefPubMedGoogle Scholar
  42. 42.
    Jorenby DE, Leischow SJ, Nides MA et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691CrossRefPubMedGoogle Scholar
  43. 43.
    Cox LS, Patten CA, Niaura RS et al (2004) Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 19:828–834CrossRefPubMedGoogle Scholar
  44. 44.
    Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev: CD000031Google Scholar
  45. 45.
    Rigotti NA, Munafo MR, Stead LF (2007) Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev: CD001837Google Scholar
  46. 46.
    Rigotti NA, Munafo MR, Stead LF (2008) Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 168:1950–1960CrossRefPubMedGoogle Scholar
  47. 47.
    Shiffman S, Johnston JA, Khayrallah M et al (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33–40CrossRefGoogle Scholar
  48. 48.
    Piper ME, Federmen EB, McCarthy DE et al (2008) Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol 117:94–105CrossRefPubMedGoogle Scholar
  49. 49.
    Teneggi V, Tiffany ST, Squassante L et al (2005) Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology 183:1–12CrossRefPubMedGoogle Scholar
  50. 50.
    Schnoll RA, Rothman RL, Lerman C et al (2004) Comparing cancer patients who enroll in a smoking cessation program at a Comprehensive Cancer Center with those who decline. Head Neck 26:278–286CrossRefPubMedGoogle Scholar
  51. 51.
    Gonzales D, Rennard SI, Nides M et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55CrossRefPubMedGoogle Scholar
  52. 52.
    Dy SM, Lorenz KA, Naeim A et al (2008) Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26:2886–2895Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Robert A. Schnoll
    • 1
    • 6
    Email author
  • Elisa Martinez
    • 2
  • Kristina L. Tatum
    • 2
  • Dorothy M. Weber
    • 2
  • Natalie Kuzla
    • 2
  • Marcella Glass
    • 2
  • John A. Ridge
    • 2
  • Corey Langer
    • 3
  • Curtis Miyamoto
    • 4
  • E. Paul Wileyto
    • 1
  • Frank Leone
    • 5
  1. 1.Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Fox Chase Cancer CenterPhiladelphiaUSA
  3. 3.Abramson Cancer CenterUniversity of PennsylvaniaPhiladelphiaUSA
  4. 4.Department of Radiation OncologyTemple University HospitalPhiladelphiaUSA
  5. 5.Department of Pulmonary Medicine, Presbyterian Medical Center - 1 PHIUniversity of PennsylvaniaPhiladelphiaUSA
  6. 6.Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations